This segment focuses on the research, development, and commercialization of innovative therapies for various eye diseases and conditions. Ocular Therapeutix utilizes its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release products. Research and development activities include preclinical studies, clinical trials, and formulation optimization. The segment's therapeutic areas include post-surgical ocular inflammation and pain, allergic conjunctivitis, wet age-related macular degeneration, open-angle glaucoma, dry eye disease, and dry age-related macular degeneration. Products like DEXTENZA and ReSure Sealant are marketed to improve patient outcomes and reduce the therapeutic burden. The company's market positioning is enhanced through strategic collaborations with companies like Regeneron and AffaMed Therapeutics. Future opportunities include expanding the product pipeline and geographic reach. Regulatory and clinical aspects involve obtaining FDA approvals and conducting clinical trials. Partnerships with other pharmaceutical companies are crucial for product development and commercialization.

This segment is dedicated to the development of advanced treatments for retinal diseases, including wet age-related macular degeneration (wet AMD). Ocular Therapeutix is leveraging its hydrogel technology to create sustained-release formulations of therapeutic agents, such as axitinib (OTX-TKI). Research and development efforts involve preclinical studies, Phase 1 clinical trials, and formulation advancements. The segment's focus is on improving vision and reducing the frequency of treatments for patients with retinal diseases. The company aims to provide innovative solutions that address unmet medical needs in the retinal space. Market positioning is strengthened through collaborations with companies like Regeneron, which provides access to VEGF-targeting compounds. Future opportunities include expanding the pipeline with additional retinal disease targets and therapies. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals. Partnerships are essential for accessing advanced technologies and expanding market reach.

This segment concentrates on developing therapies for glaucoma and dry eye disease. Ocular Therapeutix is developing OTX-TIC, a travoprost intracameral implant, for the treatment of open-angle glaucoma or ocular hypertension. Additionally, the company is working on OTX-CSI, a cyclosporine intracanalicular insert, and OTX-DED, a dexamethasone intracanalicular insert, for the treatment of dry eye disease. Research and development activities include Phase 2 clinical trials and formulation optimization. The segment aims to provide effective and convenient treatment options for patients suffering from these conditions. Market positioning is enhanced through partnerships with companies like AffaMed Therapeutics. Future opportunities include expanding the product portfolio and geographic reach. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals. Collaborations are crucial for product development and commercialization.